- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: AK-602 | GW 873140 | GW873140A
Compound class: Synthetic organic
Comment: Aplaviroc was being investigated in clinical trial as a potential treatment for HIV infection. Concerns over liver toxicity  and low efficacy  lead to termination of the development project.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, Steel H, Kleim JP, Bonny T, Millard J et al.. (2008)
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Antivir Ther (Lond.), 13 (2): 297-306. [PMID:18505181]
2. Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF, Arnold E, Mitsuya H. (2006)
Structural and molecular interactions of CCR5 inhibitors with CCR5.
J Biol Chem, 281: 12688-12698. [PMID:16476734]
3. Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, Kabeya K, Clumeck N. (2008)
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140).
Antimicrob Agents Chemother, 52 (3): 858-65. [PMID:18070967]